ClinicalTrials.Veeva

Menu
E

Eye Clinic Albury Wodonga | Albury, Australia

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

KHK4951
Faricimab
Triamcinolone Acetonide
EYE201
VX-01
EYP-1901
BRX011
AB154
MK-8748
ANX007

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

10 of 13 total trials

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.

Active, not recruiting
Wet Age Related Macular Degeneration
wAMD
Drug: Aflibercept (2.0 mg)
Drug: EYP-1901

Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD).Available standard (usual) treatments for NVAMD, s...

Enrolling
Choroidal Neovascularization
Age-Related Macular Degeneration
Drug: Tiespectus
Drug: Aflibercept
Status recently updated

This study aims to evaluate the safety and efficacy of BRX011, an oral medication, taken once daily by participants with geographic atrophy secondary...

Begins enrollment this month
Enrolling
Geographic Atrophy
Drug: Placebo
Drug: BRX011

This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have Geographic Atroph...

Enrolling
Age-related Macular Degeneration (AMD)
Geographic Atrophy (GA)
Drug: Placebo
Drug: Pozelimab

The primary purpose of the study is to determine if IVT injections of vonaprument every month reduce vision loss in participants with dry AMD with GA.

Active, not recruiting
Geographic Atrophy
Drug: Vonaprument
Other: Sham Administration

The goal of this clinical trial is to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of VX-01 as stand-alone treatmen...

Enrolling
NPDR - Non Proliferative Diabetic Retinopathy
Diabetic Retinopathy
Drug: VX-01
Drug: Placebo

A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration

Enrolling
Neovascular Age-Related Macular Degeneration (nAMD)
Biological: 4D-150 IVT (3E10 vg/eye)
Biological: EYLEA® (aflibercept) Injection 2 mg (0.05mL)

The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with DME.

Active, not recruiting
Diabetic Macular Edema (DME)
Drug: KHK4951
Drug: Aflibercept Injection

The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with nAMD.

Active, not recruiting
Neovascular Age-Related Macular Degeneration (nAMD)
Drug: Aflibercept Injection
Drug: KHK4951

This study will assess a pragmatic, treat and extend regimen of faricimab against the standard of a fixed dosing regimen.

Active, not recruiting
Diabetic Macular Edema
Drug: Faricimab

Trial sponsors

Kyowa Kirin logo
4
A
Arcus Biosciences logo
C
E
E
Ionis Pharmaceuticals logo
McMaster University logo
Regeneron Pharmaceuticals logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems